Chris Martin, ADC Therapeutics CEO

ADC Ther­a­peu­tics sells off roy­al­ty share for lead an­ti­body-drug con­ju­gate in $325M deal

ADC Ther­a­peu­tics will re­ceive $225 mil­lion in cash and an ad­di­tion­al $100 mil­lion in near-term mile­stones as part of a roy­al­ty sale with Health­Care Roy­al­ty for its lead an­ti­body-drug con­ju­gate Zyn­lon­ta and in­ves­ti­ga­tion­al CD25 can­di­date cami­dan­lum­ab tesirine (Ca­mi), the com­pa­nies said Thurs­day.

The deal snares Health­Care Roy­al­ty a 7% roy­al­ty on world­wide net sales and li­cens­ing for both drugs, which can be ex­pand­ed up to 10%. The deal ends when the $325 mil­lion has been re­couped be­tween 2.25x and 2.5x, ADC said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.